Active substance
Factor xiii
- Health Canada 2
- UK MHRA 1
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CORIFACT 1250 | 02418746 | 1250 UNIT / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | CSL BEHRING CANADA INC |
| CORIFACT 250 | 02418738 | 250 UNIT / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | CSL BEHRING CANADA INC |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| FIBROGAMMIN 250/1250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION OR INFUSION | PL 15036/0006 | CSL BEHRING GMBH | POM |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.